NCT07243236 Impact of Vaccine Funding by the National Health Insurance on Vaccination Coverage Among Patients Targeted by Current Vaccination Recommendations and Followed in Outpatient Consultations
| NCT ID | NCT07243236 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Condition | Healthcare Providers |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,920 participants |
| Start Date | 2025-11-19 |
| Primary Completion | 2027-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,920 participants in total. It began in 2025-11-19 with a primary completion date of 2027-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of our study is to evaluate the impact of vaccine funding for patients seen in outpatient consultations within four healthcare institutions in the Ile-de-France region in France, made possible through the establishment of a tripartite agreement between the hospital group, the Île-de-France Regional Health Agency (ARS IDF), and the Primary Health Insurance Fund (CPAM).
Eligibility Criteria
Inclusion Criteria: For patients: 1. For the assessment of pneumococcal coverage among patients eligible for this vaccination: * Individuals aged 18 years or older, * Individuals followed in outpatient consultations within a department and healthcare institution participating in the project; * Individuals eligible for pneumococcal vaccination against according to current French recommendations, * Individuals meeting the eligibility conditions and receiving care under long-term illness coverage (ALD) or benefiting from complementary universal health coverage (C2S) or state medical aid (AME). 2. For the assessment of pertussis vaccination among pregnant women: * Women aged 18 years or older, * Women who have had at least one follow-up outpatient consultation from 20 weeks of gestation in a maternity ward participating in the project, * Women in the immediate postpartum period (during their maternity stay) who have given birth to one or more live children and delivered after 36 weeks of gestation, * Women who have declared their pregnancy and are covered under maternity insurance (i.e., from the first day of the sixth month of pregnancy until the 12th day after delivery). For healthcare professionals: all vaccinating healthcare providers working in a participating department or center. Exclusion Criteria: * Individuals seen in settings other than outpatient consultations (day hospital, week hospital, conventional hospitalization, International Vaccination Center).
Contact & Investigator
Marie LACHATRE, MD
STUDY DIRECTOR
Hôpital Cochin - APHP
Frequently Asked Questions
Who can join the NCT07243236 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Healthcare Providers. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07243236 currently recruiting?
Yes, NCT07243236 is actively recruiting participants. Contact the research team at marie.lachatre@aphp.fr for enrollment information.
Where is the NCT07243236 trial being conducted?
This trial is being conducted at Paris, France, Fontainebleau, France, Montereau-Fault-Yonne, France, Nemours, France and 2 additional locations.
Who is sponsoring the NCT07243236 clinical trial?
NCT07243236 is sponsored by Assistance Publique - Hôpitaux de Paris. The principal investigator is Marie LACHATRE, MD at Hôpital Cochin - APHP. The trial plans to enroll 2,920 participants.